Top-down therapy for Crohn's disease: rationale and evidence.
about
Retrospective cohort study of anti-tumor necrosis factor agent use in a veteran populationUse of immunomodulators and biologic therapies in children with inflammatory bowel disease.New Applications for Traditional Drugs in Inflammatory Bowel Disease: What Do Cochrane Reviews Tell Us?Infliximab treatment induces levels of the active azathioprine metabolite TGTP in Crohn's disease.
P2860
Top-down therapy for Crohn's disease: rationale and evidence.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Top-down therapy for Crohn's disease: rationale and evidence.
@en
Top-down therapy for Crohn's disease: rationale and evidence.
@nl
type
label
Top-down therapy for Crohn's disease: rationale and evidence.
@en
Top-down therapy for Crohn's disease: rationale and evidence.
@nl
prefLabel
Top-down therapy for Crohn's disease: rationale and evidence.
@en
Top-down therapy for Crohn's disease: rationale and evidence.
@nl
P2860
P356
P1433
P1476
Top-down therapy for Crohn's disease: rationale and evidence.
@en
P2093
G R D'Haens
P2860
P304
P356
10.1179/ACB.2009.092
P577
2009-11-01T00:00:00Z